Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Bigelow Investment Advisors LLC

Bigelow Investment Advisors LLC decreased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,897 shares of the medical instruments supplier’s stock after selling 103 shares during the period. Bigelow Investment Advisors LLC’s holdings in Becton, Dickinson and Company were worth $664,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Aspiriant LLC increased its holdings in shares of Becton, Dickinson and Company by 18.6% during the 1st quarter. Aspiriant LLC now owns 1,330 shares of the medical instruments supplier’s stock worth $305,000 after buying an additional 209 shares during the last quarter. State of Alaska Department of Revenue grew its position in Becton, Dickinson and Company by 2.1% during the first quarter. State of Alaska Department of Revenue now owns 33,648 shares of the medical instruments supplier’s stock valued at $7,707,000 after acquiring an additional 700 shares during the period. Clarius Group LLC increased its stake in Becton, Dickinson and Company by 55.5% during the first quarter. Clarius Group LLC now owns 2,121 shares of the medical instruments supplier’s stock worth $486,000 after acquiring an additional 757 shares during the last quarter. Insigneo Advisory Services LLC raised its holdings in shares of Becton, Dickinson and Company by 19.3% in the 1st quarter. Insigneo Advisory Services LLC now owns 3,760 shares of the medical instruments supplier’s stock worth $861,000 after purchasing an additional 608 shares during the period. Finally, Bfsg LLC raised its holdings in shares of Becton, Dickinson and Company by 1.1% in the 1st quarter. Bfsg LLC now owns 24,964 shares of the medical instruments supplier’s stock worth $5,718,000 after purchasing an additional 271 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $168.54 on Thursday. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The business has a 50 day moving average price of $180.85 and a two-hundred day moving average price of $212.00. The firm has a market cap of $48.30 billion, a PE ratio of 32.16, a price-to-earnings-growth ratio of 1.28 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The business’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.17 earnings per share. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be paid a $1.04 dividend. The ex-dividend date is Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.47%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 79.39%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the sale, the executive vice president now directly owns 4,575 shares of the company’s stock, valued at approximately $783,194.25. This represents a 20.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 479 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the transaction, the executive vice president now directly owns 4,887 shares of the company’s stock, valued at $964,107.36. This trade represents a 8.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BDX. Stifel Nicolaus dropped their target price on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Bank of America lowered shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price objective for the company. in a research report on Thursday, May 1st. Barclays reduced their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a report on Tuesday, June 3rd. Morgan Stanley lowered their price target on Becton, Dickinson and Company from $280.00 to $196.00 and set an “overweight” rating for the company in a report on Tuesday, May 6th. Finally, Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $219.22.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.